In 30 atherosclerotic patients different serum analytes and neopterin concentrations in serum and urine were determined before and after Heparin-Induced Extracorporeal LDL and Fibrinogen Precipitation therapy. Neopterin concentrations in serum of all 30 patients were increased (mean=9.1S nmol/l, SD=3.23) compared to age matched healthy people (mean=5.34 nmol/l, SD=2.70) and were significantly lowered after H.E.L.P therapy (mean=S.22 nmol/l; SD=3.22, p=0.002, t-test) . These results suggest the involvement of the cellular immune system in the occurrence of atherosclerosis. Further neopterin, the macrophagederived immune activation marker, is significantly correlated with fibrinogen (linear correlation coefficient r=0.36, p=0.05). Long-term neopterin concentrations in serum of 4 patients (three with coronary heart disease and one with Papilla edema), from the first up to the gI', respectively 12th therapy decreased, in contrast to fibrinogen which stayed stable or even increased during long-term treatment.
Introduction
The activation of macrophages (1, 2) and consequently, the activation of the cellular immune system have been implicated to be involved in the initiation and progression of atherosclerosis (3) .
Neopterin is synthesized by human monocytes/macrophages upon stimulation by interferon y which is produced by activated T-Iymphocytes (4, 5) , and is increased in a number of diseases involving cellular immune system activation such as infections and autoimmune disorders (6) (7) (8) (9) . §Corresponding author: Ass.Prof. Dr. Karoline Vrecko, Institut fur Medizinische Chemie und Pregl Laboratorium, Harrachgasse 21, A -8010 Graz, Austria, Tel.: ( ++43 ) 316380/4166, Fax: ( ++43 ) 316380/ 9610 Many of the conventional serum analytes which are known to be increased in atherosclerosis, such as cholesterol, triglycerides and LDL, can be precipitated and washed out extra corporally from the serum of atherosclerotic patients by Heparin-Induced Extracorporeal LDL and Fibrinogen Precipitation (H.E.L.P. ) therapy (10) within two hours. Recent studies focus their attention especially on fibrinogen, which is assumed to be risk factor for atherosclerosis well comparable with the lipid parameters (11) (12) (13) (14) , and concentrations of more than 300 mg/ dl are already connected with an increased cardiovascular risk (15) . Also this acute phase protein can be eliminated by H.E.L.P. therapy.
The aim of this study was to fmd whether the cellular immune system, represented by neopterin, is involved in the occ"Urrence of atherosclerosis, whether neopterin correlates \\'ith any of the above mentioned serum analytes, and " 'hether neopterin concentrations are influenced by H.E.L.P. therapy.
Materials and Methods
In 30 patients (10 with coronary heart disease [CHD], 8 men, 2 women, age: 57.9 years, SD=10.2; 6 with peripheral occlusive vessel disease [POVD], 5 men, 1 woman, age: 57.8 years, SD=6.8; 7 with Papilla edema [PE], 5 men, 2 women, age: 61.1 years, SD=9.6; 3 with hyperlipidemia, 2 men, 1 woman, age: 47.0 years, SD=7.9; 1 man with cerebrovascular insufficiency, age: 52.0 years and 3 patients with other atherosclerotic diseases, 2 men, 1 woman, age: 50.3 years, SD=12.5) neopterin concentrations in serum were determined before and after the first H.E.L.P. therapy session by using the ELItest Neopterin kit (BRAHMS Diagnostica, Berlin, FRG). In urine, neopterin was determined utilizing its native fluorescence after separation by high performance liquid chromatography, using previously described procedures (6, 16) . Urine was diluted with 15mrnol r-I potassium phosphate buffer (pH=6.4), containing 5.4 mrnol I-I disodium diaminoethylene tetraacetate (EDTA). This bufier without EDTA was also used as mobile phase at a flow rate of 1 ml min-I. A ready to use cartridge (Hibar LiChroCart, 125x4 mm inner diameter, E. Merck, Darmstadt, Germany) served as analytical column, which was protected by a guard cartridge (Hibar LiChroCart, 4x4 mm inner diameter, E. Merck). Both columns were packed with 7 )J.m reversed phase CIs-material (LiChrosorb, RP 18, E. Merck). Neopterin was quantitated by its native fluorescence (353 nm excitation, 438 emission wavelengths) at room temperature. In order to compensate for differences in urinary total concentrations, urinary neopterin concentrations are commonly related to urinary creatinine which was detected using its UV absorption at a wavelength of 230 run (Spectro Monitor D, LDC, Milton Roy, Riviera Beach, Fl) in the same analytical run. Concentrations of both analytes were calibrated by external standard methods.
Cholesterol, LDL, triglycerides and fibrinogen were measured by using a photometer (Cobas Misa, La Roche, Vienna, Austria), HDL by the immuno-f1u-orescence method (Abbott, Vienna, Austria). Counting white and red blood cells had been performed by a coulter counter (Cebas Minos STE, Roche, Vienna, Austria).
The H.E.L.P. therapy is based on the principle of precipitation of dangerous compounds in acid medium (10) . The patients are at first connected to the extracorporeal circulation by a butterfly needle or a catheder in the vena cava. Mter separation of plasma and blood cells by means of a filter, the resulting plasma is mixed with an equal volume of acetate buffer (pH 4.85) and a surplus of heparin (100 IE per ml buffer). Under these conditions (pH of 5.12), fibrinogen, cholesterol, LDL, lipoprotein a and triglycerides are precipitated. These precipitates are removed by a 0.4 mrn polycarbon filter. Subsequently heparin is absorbed by an anion exchange filter, and a bicarbonate dialysis must be carried out to increase the pH to physiological conditions. Afterwards the plasma is re-infused to the blood stream of the patient. During this cycle up to three liters of plasma undergo the precipitation process in 2 to 2.5 hours (Plasmat secura, B. Braun Inc., Melsungen, FRG).
Statistical evaluation was done by SPSS 6.0 for WINDOWS. Data were tested by KOLMO-GOROW-SMIRNOV test for absence versus presence of normal distribution. T-test and one-way ANOVA were employed to identify significant differences of serum analytes distributions. Linear correlation co-efficients and regression lines were calculated for analysing interpendences and trends.
Results
Concentrations of all serum analytes in the 30 investigated subjects were normally distributed.
Mean neopterin concentrations in serum from all 30 patients with atheroslerosis were increased (mean= 9.18 nmol/l, SD=3.28) compared to age-matched healthy subjects (mean=5.34 nmol/l, SD=2.70). Comparing neopterin in serum of the 30 patients before and after a H.E.L.P. therapy session, we found a significant decrease to a mean of 8.22 nM/ I, SD= 3.27 (t-test, p=0.002). No significant change of urinary neopterin concentration could be found. As confirmed by several studies (10, 14) significant decreases in concentrations of fibrinogen, cholesterol, LDL, HDL, triglycerides and number of leukocytes were observed ( Table 1) .
The mean neopterin and fibrinogen concentrations in serum before and after each H.E.L.P. session in the three patient groups (group 1 = 7 patients with PE, group 2=6 patients with POVD, group 3 = 10 patients with CHD) are shown in Table 2 . As fibrinogen was significantly decreased in all groups, neopterin was significantly lowered only in group 3. Groups 1 and 2 also showed decreased levels of neopterin. Using one-way ANOVA to judge whether there exists differences of the mean values of neop- therapy with all other semm analytes were tested too, but only the correlation with fibrinogen was significant. A strongly significant correlation was expectedly found between neopterin before and neopterin after H.E.L.P. therapy (r=0.89, p<O.OOl ) .
The difference between fibrinogen before and after a H.E.L.P. session is strongly dependent on fibrinogen levels before (1'=0.724, p<O.Ol) ( Figure  2 ). This is not the case for neopterin.
The long-term effect of H.E.L.P. therapy is shown in Table 3 . Neopterin concentration in semm before the first, and before 9 th , respectively 12th, successive H.E.L. P. therapy sessions showed a significant decreasing in two patients with CHD and in other two patients (CHD and PE), studied longitudinally, neopterin also shows a decreasing but this trend did not reach significance (Figure 3 ) . In contrast to that fibrinogen concentrations stayed stable or even increased . HDL seemed to increase slightly during long therapy duration.
Discussion
Hypertonia, smoking, diabetes, dyslipidemia and adipositas are established as main causes for atherosclerosis. In recent studies it was shown that also elevated concentrations of fibrinogen may be involved in tl1e patl10genesis of atherosclerosis (15, (17) (18) (19) . Fibrinogen, a most important acute phase protein, is synthesized in the liver and is regulated by a positive feed back by its own catabolic products and by a number of cytokines, especially of interleukin 6 (20) . Acute inflammation processes can increase fibrinogen to more than 100%. Therefore, fibrinogen is a very sensitive marker for chronic inflammations which is thought to contribute to the pathophysiology of atherosclerosis (21) . Neopterin has been shown to be a sensitive indicator for the activation of cell-mediated immune reactions (22, 23) . The increase of neopterin concentration in serum of subjects suffering from atherosclerosis confirms the involvement of the cellular immune system. Our results agree well with a study where elevated serum neopterin levels were observed in patients with carotid atherosclerosis (24) , and in patients with severe atherosclerosis irrespective of the anatomical site (25) . The small but invariably significant increase of neopterin may be a signal for chronic inflammations of the blood vessel system in response to multiple, local and microscopic intimal lesions.
H.E.L.P therapy is able to decrease serum lipids, especially cholesterol, LDL, lipoprotein a, triglycerides and also fibrinogen, and therefore to decrease the incidence ofCHD (26, 27) . The beneficial influence of H.E.L.£ therapy on CHD is well docuPteridines / Vol. 10/ No.4 mented (28). Other plasma proteins as albumines and globulines are not influenced by this therapy (29) .
In our experiments, after therapy we found significantly decreased serum lipid analytes as well as fibrinogen. Also neopterin decreased slightly and partly significantly after therapy. We think. that this can be explained as wash-out effect. Anyway, we think that the behavior of neopterin during a H.E.L.P session is not of clinical interest. Fibrinogen concentrations (before versus after therapy) decreased significantly in all groups, confirming that fibrinogen is washed-out during H.E.L.P therapy very efficiently.
By testing the correlation of neopterin before H.E.L.P. therapy in the 30 patients collective with all other variables, a significant correlation was found only with fibrinogen. As fibrinogen is increased in all stages of atherosclerosis and participates already in the pathology of early local lesions by accumulating in the area of vessel lesions, we assume that the cell mediated immune system becomes activated already at this early stage. The role of activated macrophages which synthesize neopterin upon stimulation by interferon y, a cytokine originating from activated T-cells, and the role of circulating cytokines in atherogenesis have been described (1-3, 21, 30, 31) , especially regarding the influence on lipid metabolism via uptake and conver-sion of certain lipids. Hannson et al. (32) showed the regulation of vascular smooth muscle proliferation by interferon y. In addition, fibrinogen seems to stimulate the migration of smooth muscle cells from deeper layers of the vascular wall into the lesion as well as to stimulate the proliferation at the lesion (15) . As interferon y and fibrinogen seem to exert similar intluences on atherogenesis, especially on the growth of lesions, the correlation between neopterin and fibrinogen appears plausible.
The significant correlation between fibrinogen verSLlS the difference of fibrinogen before and after a H.E.L.P. session shows that the higher the fibrinogen concentration before therapy, the better the wash-out effect by the H .E.L.P. procedure.
In four patients, we had the opportunity to smdy the long-term effect of therapy. Mter 9 H.E.L.P. sessions within 120 d ays, respectively 12 therapies within 200 days, neopterin (compared before the 1 st respectively before the 9 th or 12th therapy) invariably decreased (in two patients the decreasing trend was even significant). This is in marked contrast with fibrinogen, which stayed stable or even increased slightly in the same patients . As a desired effect of H.E.L.P. therapy it h as been claimed that HDL increases after a few sessions (10) . In our investigations we also observed this trend.
Our data show that activation of the cellular in11llune system, assessed by neopterin measurement might indeed be involved in the pathogenesis of atherosclerosis. The two subpopulations of CD4+ T cells might be involved: TH 1 cells secrete interferon yand IL-2, and TH 2 produce among o ther c\1:okines mainly IL-6. Interferon y regulates n eoptcrin synthesis (6, 22, 23) and vascular smooth mLlScle proliferation (3 2 ), and IL-6 regulates fibrinogen 120), which in turn influences the grow th of atherosclerotic lesions. The decrease of neopterin after lo ng term treatment leads one to suppose an improvement of the chronic immune stimulation towards normal. This might reflect a decrease in the inflammation process of the blood vessel system, resulting in a delay or even stopping of lesions growth by repeated treatment with H.E.L.P. therapIes.
